Reuters logo
BRIEF-Zealand Pharma: 2014 royalty revenue from Sanofi's ex-US sales DKK 20.4 mln
February 5, 2015 / 7:24 AM / in 3 years

BRIEF-Zealand Pharma: 2014 royalty revenue from Sanofi's ex-US sales DKK 20.4 mln

Feb 5 (Reuters) - Zealand Pharma A/S :

* Reports Lyxumia royalty revenue for 2014 and informs of developmental and regulatory updates by Sanofi

* Royalty revenue to Zealand from Sanofi’s ex-US sales of Lyxumia in 2014 amounts to 20.4 million Danish crowns / 2.7 million euros ($3.06 million)

* Says pending completion of ELIXA and Lixilan Phase III trials, Sanofi plans for US regulatory submissions for Lyxumia in Q3 2015 and for US and EU regulatory submission for Lixilan in Q4 2015 Source text for Eikon: Further company coverage: ($1 = 0.8818 euros) (Gdynia Newsroom)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below